The UK KOL starts patients on csDMARDs before adalimumab biosimilars, uses IL-17 inhibitors for severe skin, and favors dose escalation over switching. The KOL notes Bimzelx dominates IL-17 use given Cosentyx's waning efficacy, sees Tremfya and Skyrizi as interchangeable, and expects GLP-1 agonists to shrink biologic demand. The interview closes with emerging options, including TYK2 inhibitors replacing JAKs on safety and sonelokimab needing lower cost to compete, while pain remains largely unmet. 

This interview was conducted on March 18, 2026.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.